- World rank, 2022–2025
- #8,163 of 28,054 · #15,570 all time
- Rank in Finland
- #28 of 80
- Research works
- 208 ▲ 594% vs 2013–17
- Citations
- 4.6k 22.3 per fractional work
- Top-10% rate
- 26.1% record average 16.5%
- Open access
- 64% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Pharmacology, Toxicology and Pharmaceutics, 5.8×. Every wedge is a field page.
- Pharmacology, Toxicology and Pharmaceutics 5.8×
- Immunology and Microbiology 5.8×
- Biochemistry, Genetics and Molecular Biology 4.1×
- Veterinary 3.4×
- Chemistry 3.0×
- Medicine 2.6×
- Economics, Econometrics and Finance 1.1×
- Mathematics 0.8×
- Nursing 0.7×
- Materials Science 0.5×
- Neuroscience 0.5×
- Health Professions 0.4×
- Computer Science 0.4×
- Decision Sciences 0.2×
- Environmental Science 0.2×
- Physics and Astronomy 0.1×
- Engineering 0.1×
- Agricultural and Biological Sciences 0.1×
- Chemical Engineering 0.1×
- Business, Management and Accounting 0.0×
- Social Sciences 0.0×
- Psychology 0.0×
Who are the top researchers at AstraZeneca (Finland)?
Ranked on the composite score, Adam Platt lead among researchers whose main affiliation is AstraZeneca (Finland).
- 1 Adam Platt Finland · #758,964 worldwide 44 citations · 17 works
Which keywords describe research at AstraZeneca (Finland)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Inflammation, Heart Failure, Epidemiology, Diagnosis, Treatment, Cardiovascular Disease, Medicinal Chemistry and Pharmacokinetics.
- Regulatory T Cells
- spirometry
- Drug Target Identification
- Respiratory
- Immunity
- Fibrosis
- Molecular Docking
- TGF-ß
- Type 2 Diabetes
- Allergic Diseases
- Glycemic Control
- Metabolic Syndrome
- Global Burden
- Clinical Trials
- Genetics
- Oxidative Stress
- Cancer
- Heart Failure
- Diagnosis
- Epidemiology
- Inflammation
- Treatment
- Cardiovascular Disease
- Machine Learning
- Management
- Medicinal Chemistry
- Biomarkers
- Pharmacokinetics
- Immunology
- Asthma
- Insulin Therapy
- Eosinophils
- Clinical Guidelines
- Guidelines
- Cardiovascular Outcomes
- Glucose Control
- Monoclonal Antibodies
- COPD
- Virtual Screening
- Chronic Kidney Disease
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Inflammation10▲ 4.5×48 topics
- Epidemiology9▲ 2.1×35 topics
- Treatment6▲ 4.5×10 topics
- Diagnosis6▲ 5.4×12 topics
- Cardiovascular Disease5▲ 4.4×21 topics
- Heart Failure5▲ 11×11 topics
- Machine Learning5▲ 1.43×11 topics
- Cancer5▲ 3.3×27 topics
- Management4▲ 4.9×10 topics
- Oxidative Stress4▲ 2.3×28 topics
- Medicinal Chemistry4▲ 13×8 topics
- Genetics4▲ 5.1×6 topics
- Biomarkers4▲ 4.9×12 topics
- Clinical Trials4▲ 4.9×10 topics
- Pharmacokinetics4▲ 12×4 topics
- Global Burden3▲ 5.8×4 topics
- Immunology3▲ 29×2 topics
- Metabolic Syndrome3▲ 3.7×14 topics
- Asthma3▲ 31×2 topics
- Glycemic Control3▲ 19×4 topics
- Insulin Therapy3▲ 23×3 topics
- Allergic Diseases3▲ 46×1 topic
- Eosinophils3▲ 46×1 topic
- Type 2 Diabetes3▲ 12×4 topics
- Clinical Guidelines3▲ 8.4×4 topics
- TGF-ß3▲ 16×4 topics
- Guidelines3▲ 5.1×6 topics
- Molecular Docking2▲ 18×2 topics
- Cardiovascular Outcomes2▲ 40×1 topic
- Fibrosis2▲ 12×4 topics
- Glucose Control2▲ 40×1 topic
- Immunity2▲ 5.5×7 topics
- Monoclonal Antibodies2▲ 24×3 topics
- Respiratory2▲ 23×2 topics
- COPD2▲ 32×1 topic
- Drug Target Identification2▲ 23×1 topic
- Virtual Screening2▲ 23×1 topic
- spirometry2▲ 32×1 topic
- Chronic Kidney Disease2▲ 8.0×8 topics
- Regulatory T Cells2▲ 17×4 topics
Which research topics does AstraZeneca (Finland) publish most on?
By volume in 2022–2025: Asthma and respiratory diseases, Diabetes Treatment and Management, Computational Drug Discovery Methods and Chronic Obstructive Pulmonary Disease (COPD) Research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Asthma and respiratory diseases Physiology 3 works
- 2 Diabetes Treatment and Management Endocrinology, Diabetes and Metabolism 2 works
- 3 Computational Drug Discovery Methods Computational Theory and Mathematics 2 works
- 4 Chronic Obstructive Pulmonary Disease (COPD) Research Pulmonary and Respiratory Medicine 2 works
- 5 Inhalation and Respiratory Drug Delivery Pulmonary and Respiratory Medicine 2 works
- 6 IL-33, ST2, and ILC Pathways Immunology 2 works
- 7 CRISPR and Genetic Engineering Molecular Biology 1 works
- 8 Neonatal Respiratory Health Research Pulmonary and Respiratory Medicine 1 works
- 9 Cystic Fibrosis Research Advances Pulmonary and Respiratory Medicine 1 works
- 10 Heart Failure Treatment and Management Cardiology and Cardiovascular Medicine 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has AstraZeneca (Finland)'s research output changed?
Output in 2018–2022 was 594% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Espoo
- Aalto University
- VTT Technical Research Centre of Finland
- Nokia (Finland)
- Helsinki Institute for Information Technology
- Geological Survey of Finland
- Orion Corporation (Finland)
- Microsoft (Finland)
- Neste Oil (Finland)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.